Search the Newsreel

NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery

NovoCure (NVCR) shares surged after Q2 2026 earnings, pushing past technical resistance and shifting investor focus from a past clinical trial failure to the commercial potential of its Optune Pax platform. The Q2 results reflect the first full quarter of Optune Pax revenue, a …

Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes

Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval for its brain therapy candidate. In intra-day trading, the stock climbed to a …

Novocure Reports Second Quarter 2026 Financial Results

Novocure reported strong second quarter 2026 financial results with record net revenues of $184 million, a 16% increase year-over-year, driven by 18% global active patient growth. The company also received CE Mark approval for Optune Pax® for locally advanced pancreatic cancer in the EU, …

NovoCure surges on Q2 results

NovoCure (Nasdaq: NVCR) saw its share price jump by nearly 25% after reporting strong Q2 2026 results, handily beating analyst estimates on both revenue and earnings. The company reported $184 million in revenue, a 16% increase year-over-year, and narrowed its net loss to $15 …

12 Health Care Stocks Moving In Thursday's Intraday Session

This article lists 12 healthcare stocks experiencing significant movement during Thursday's intraday trading session. It highlights several gainers, including NovoCure, Zhengye Biotechnology, Neuphoria Therapeutics, Medpace Holdings, Gelteq, and Advanced Biomed, along with their respective percentage increases and market capitalizations. Conversely, it also details losers …

Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook

Novocure reported record second-quarter net revenue of $183.6 million, a 16% increase year-over-year, driven by the expansion of its TTFields therapy. The company also raised its 2026 revenue guidance to $710 million-$725 million and improved its adjusted EBITDA outlook, fueled by the commercial growth …

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

Novocure Ltd earnings beat by $0.20, revenue topped estimates

Novocure Ltd (NASDAQ: NVCR) exceeded analyst expectations in its second-quarter earnings, reporting an EPS of $-0.13, which was $0.20 better than the estimated $-0.33. The company also surpassed revenue estimates, bringing in $183.6M against a consensus of $172.72M. Novocure provided a strong revenue guidance …

NovoCure: Q2 Earnings Snapshot

This article provides a brief "earnings snapshot" for NovoCure's Q2 performance. Due to the limited content, specific financial details are not available.

NovoCure (NASDAQ: NVCR) lifts Q2 revenue 16% to $183.6M amid new approvals

NovoCure (NASDAQ: NVCR) reported a 16% year-over-year increase in Q2 2026 revenue, reaching $183.6 million, driven by an 18% growth in active patients and international market expansion. The company's Adjusted EBITDA turned positive at $10.8 million, indicating improving operating leverage. Key developments include FDA …

NOVOCURE ($NVCR) Releases Q2 2026 Earnings | NVCR Stock News

Earnings call transcript: NovoCure beats Q2 2026 forecasts, shares jump 16%

NovoCure reported record net revenues of $184 million in Q2 2026, a 16% year-over-year increase, driven by growth in Optune Gio, Lua, and Pax, with an 11% rise in active Optune Gio patients. The company updated its full-year revenue guidance to $710-$725 million and …

Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?'

Novocure stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment, Optune. Continue Reading

Novocure in focus: Pancreatic cancer launch takes spotlight

Novocure (NASDAQ: NVCR) is set to report its second-quarter earnings, with investor attention focused on the early performance of its newly launched Optune Pax therapy for pancreatic cancer. The company aims for this therapy to become its second major revenue generator, complementing its existing …

Stocks in Focus Today, 21 July, 2026: Fluorochemicals, Nuvoco Vistas, Prestige Estates Drive Gains in Cement, Chemicals, Realty Pack

VOC Energy Trust Unitholders to Receive $4.76M on Aug. 14

VOC Energy Trust announced a quarterly distribution of $4,760,000, or $0.28 per unit, to unitholders of record on July 30, 2026, payable on August 14, 2026. This distribution reflects the net profits for the period ending June 30, 2026, based on sales volumes of …

Nuvoco Q1 FY27 net profit rises 20% to ₹160 crore

Cement manufacturer Nuvoco Vistas Corp lays bricks for ₹13K cr FY27 revenue

Lobbying Update: $160,000 of NOVOCURE INC. lobbying was just disclosed

Novocure Inc. recently disclosed $160,000 in lobbying expenditures for Q2 2026, focusing on medical device tariff issues and patient access to breakthrough products. Insider trading activity for NVCR shows 17 sales and no purchases in the last six months, with several executives selling shares. …

NovoCure (NVCR) Could Be 39% Undervalued If Its Growth Narrative Holds

NovoCure (NVCR) has shown mixed stock performance recently, with short-term gains against longer-term declines. Despite its current share price of $15.92, a prevailing narrative suggests the company is 38.9% undervalued, with a fair value of $26.07, based on potential growth from new TTFields therapy …

Earnings Preview: Novocure to Report Financial Results Pre-market on July 23

Novocure (NVCR) is scheduled to announce its financial results pre-market on July 23. Analysts estimate the company will report a quarterly loss of $0.34 per share and revenue of $137.95 million. The report will provide insights into the company's financial performance and future outlook.

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NovoCure (NVCR) is expected to report a narrower loss compared to the previous year, with revenues also projected to increase for the quarter ending June 2026. However, despite a positive earnings ESP, the company's Zacks Rank of #4 makes it difficult to definitively predict …

If EPS Growth Is Important To You, Nuvoco Vistas (NSE:NUVOCO) Presents An Opportunity

VOC Energy Trust Holds Steady Near Support Level After Marginal Decline - Overvalued Signals

VOC Energy Trust Q3 2024 Earnings: Trust Reports Net Income of $0.18 per Unit Amid Modest Stock Decline - Share Repurchase Impact

NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss

Novocure Reports First Quarter 2026 Financial Results

NovoCure Q1 Earnings Call Highlights

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

NovoCure Q4 Earnings Call Highlights

NOVOCURE ($NVCR) Releases Q4 2025 Earnings | NVCR Stock News

NovoCure: 2026 Pipeline Outlook Make This Stock A Speculative Buy (NASDAQ:NVCR)

NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges

VOC Energy Trust Releases Complete 2024 Financial Performance Details in Annual Report

South China Vocational Education Announces its 2022 Annual Results Revenue Grows Steadily to RMB516.3 million

Dividend History - VOC Energy Trust (VOC)